In an era where modern medicine strides to span further than ever before, a major advancement in the fight against cancer may be upon us. New research from the City of Hope Hospital, one of the leading cancer research and treatment institutes in the US, reveals a promising exploratory medicinal drug. This novel cancer-fighting pill, called AOH1996, has shown considerable potential in preclinical studies, raising optimism for the medical community and cancer patients around the world.
AOH1996 is designed to target the “undruggable” protein, Proliferating Cell Nuclear Antigen, typically abbreviated as PCNA. This protein is intrinsic to DNA replication and repair—it plays a central role in the growth and survival of all cancer cells, making it an excellent target for therapeutic drugs. It is reminiscent of a busy airline terminal, facilitating the essential flights of cell division and survival for cancer cells.
“PCNA is like a major airline terminal hub containing multiple plane gates. Data suggests that PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells. Our cancer-killing pill is like a snowstorm that closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells,” explains Professor Linda Malkas, one of the study’s principal investigators and a champion in this innovative area of research.
The distinguishing aspect of this new therapy is not merely the innovative method of targeting PCNA, previously viewed as “undruggable,” but the precision and selectivity of its cancer cell eradication. In the over 70 cancer cell lines tested, the drug selectively demolished cancer cells while leaving the healthy cells untouched. The method of elimination involves disrupting the delicate balance of the normal reproductive cycle of the cell, a process utilized by all rapidly dividing cancer cells.
Dr. Long Gu, the lead author of this study, expounds on the unique angle that AOH1996 offers in designing new cancer therapies. “We discovered that PCNA is one of the potential causes of increased nucleic acid replication errors in cancer cells. Now that we know the problem area and can inhibit it, we will dig deeper to understand the process to develop more personalized, targeted cancer medicines,” he says.
Moreover, the researchers unearthed another advantage of AOH1996—it enhances the susceptibility of cancer cells to standard cancer treatments that cause DNA or chromosomal damage. This finding implies it could play a crucial role in combination therapies, improving the efficacy of existing cancer treatments.
While the PCNA protein was previously considered undruggable and studies targeting it have primarily remained at the stage of laboratory experiments, a phase 1 clinical trial is currently being undertaken at the City of Hope Hospital, assessing the safety of AOH1996 in treating recurring solid cancer tumors.
In addition to its promising efficacy, AOH1996 has also shown potential in combination therapies. Studies have revealed that it enhances the susceptibility of cancer cells to standard cancer treatments that cause DNA or chromosomal damage. This means that AOH1996 can potentially improve the effectiveness of existing cancer treatments when used in combination.
The dedication of researchers at the City of Hope Hospital serves as a testament to the relentless pursuit of medical advancements, striving to make the undruggable druggable and the incurable curable. Their groundbreaking work not only reinforces the power of innovation in science and technology but also inspires hope for future conquests against cancer and other formidable diseases. With the ongoing clinical trial for AOH1996, the medical community is on the cusp of a revolutionary breakthrough in cancer treatment, bringing us one step closer to winning the battle against this devastating disease.
The study Small molecule targeting of transcription-replication conflict for selective chemotherapy was published in the journal Cell Chemical Biology.
FAQs
1. What are the potential benefits of targeting molecules or pathways?
Targeting molecules or pathways, such as KRAS or MYC, in cancer treatment may provide potential therapeutic benefits, including inhibiting tumor growth and improving patient outcomes. Additionally, targeting specific genes involved in metabolic pathways downstream of these molecules could potentially disrupt cancer cell metabolism and inhibit tumor growth.
Additionally, for testing these interventions, preclinical models, like syngeneic tumor models, are vital for understanding metabolic pathway impacts on tumor progression and the microenvironment, guiding better cancer treatment development.
2. Why Is KRAS So Hard to Hit?
KRAS has long been considered an “undruggable” protein because it lacks obvious binding sites for small-molecule drugs. This has made it challenging to develop targeted therapies against KRAS mutations, which are present in various cancers. However, recent progress, including the identification of KRAS signaling pathways and the development of combination therapies, has provided new strategies for targeting KRAS-driven cancers.
3. How does AOH1996 help treat cancer?
AOH1996 is a PCNA inhibitor that targets the protein proliferating cell nuclear antigen (PCNA), which is present in all dividing cells, including cancer cells. By blocking PCNA, AOH1996 selectively inhibits the growth of cancer cells, potentially preventing the spread of cancer throughout the body. Early in vitro and animal studies have shown promising results, suggesting that AOH1996 could be effective in treating various types of cancer.
4. Where are we now in terms of making these targets druggable?
The field of research aimed at making “undruggable” targets, such as KRAS or MYC, druggable has made significant progress in recent years. New approaches and technologies, such as PROTAC technology and small molecules that bind to MYC, have shown promise in targeting these previously considered “undruggable” proteins. However, further research is still needed to optimize the efficacy and safety of these approaches.
5. What are the future challenges for this field of research?
The field of research targeting “undruggable” proteins or pathways in cancer faces several challenges. One of the main challenges is securing sufficient resources and funding to support high-risk research in this area. Additionally, the specificity of new drug classes targeting these proteins could be challenging, and there is a need to minimize potential on-target effects on normal tissues. Public research funding support is essential to advance this field and overcome these challenges.
6. What is the study measuring?
The study measures several outcomes, including the incidence of adverse events and dose-limiting toxicities in patients receiving treatment with the PCNA inhibitor AOH1996. Adverse events will be recorded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). The study will also assess the safety and tolerability of AOH1996 and its potential effectiveness in inhibiting tumor growth in patients with advanced cancers.
